EWHealthcare · Medical DevicesThe 30 Wall Street analysts covering Edwards Lifesciences Corp. hold a median 12-month price target of $103 — +3.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Edwards Lifesciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (90): The share price has been relatively steady.
Accruals (70): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on EW, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.8% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Overweight | $110 |
| 11 Sept 2026 | BTIG | Reiterates | Buy | — |
| 11 Sept 2026 | BTIG | Reiterates | Buy | $110 |
| 28 July 2026 | UBS | Assumes | Buy | $110 |
| 25 July 2026 | Leerink Partners | Upgrade | Outperform | — |
| 24 July 2026 | JP Morgan | Maintains | Overweight | — |
| 24 July 2026 | JP Morgan | Maintains | Overweight | $100 → $105 |
| 24 July 2026 | Leerink Partners | Upgrade | Outperform | $87 → $101 |
| 24 July 2026 | Piper Sandler | Reiterates | Overweight | $100 → $101 |
| 24 July 2026 | Piper Sandler | Reiterates | Overweight | — |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 16 July 2026 | Truist Securities | Maintains | Hold | $90 → $95 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $100 → $105 |
| 13 July 2026 | RBC Capital | Maintains | Outperform | — |
| 13 July 2026 | RBC Capital | Maintains | Outperform | $100 → $110 |
| 8 July 2026 | Citigroup | Maintains | Buy | $101 → $110 |
| 8 July 2026 | Citigroup | Maintains | Buy | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $93 → $100 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EW appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Edwards Lifesciences Corp. returned +18.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 12% of US stocks
Cheaper than 15% of US stocks
Cheaper than 17% of US stocks
Cheaper than 9% of US stocks
Higher than 61% of US stocks
Higher than 18% of US stocks
Higher than 89% of US stocks
Higher than 87% of US stocks
Higher than 78% of US stocks
Higher than 61% of US stocks
Higher than 89% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Edwards Lifesciences Corp. has a market value of $57.2B and an enterprise value of $53.8B.
Revenue in the twelve months to 30 June 2026: $6.5B. The latest quarter grew 13.6% year on year.
Net income over the same four quarters: $1.0B, a 15.4% net margin.
Diluted earnings per share, trailing twelve months: $1.74.
Free cash flow in the twelve months to 30 June 2026: $1.4B, after $286.7M of capital spending.
Edwards Lifesciences Corp. spent $1.2B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 59.1×; forward P/E: 29.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Edwards Lifesciences Corp. employs 16,000 people — $407K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Edwards Lifesciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The item is a transcript of Edwards Lifesciences Corporation’s Q3 2026 earnings call; the excerpt provides no further details about the discussion.
Why it matters — The transcript may be relevant to EW watchers seeking information about the company’s quarterly call, but the supplied excerpt contains no specific business updates.
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, up 10.5%, and adjusted EPS of $0.80, up 19% from the prior year. TAVR sales rose 8.0% to $1.24 billion, while TMTT sales increased 44.0% to $207 million.
Why it matters — The results give EW watchers an update on quarterly sales and growth across its TAVR and TMTT businesses, as well as adjusted earnings.
Benzinga’s headline says an analyst covering Edwards Lifesciences turned bullish, as part of a roundup of five analyst upgrades for Wednesday. The excerpt provides no details about the analyst or rating change.
Why it matters — EW watchers may note the reported change in analyst outlook, though the excerpt gives no specifics about the upgrade.
Seeking Alpha describes a mixed backdrop for the second week of Q3 earnings: AI-related spending and business concerns weighed on some major technology companies, while S&P 500 earnings growth remained robust at 29.5%. Nine companies also confirmed delayed reporting dates, which the excerpt characterizes as a historical indicator of potential bad news.
Why it matters — The excerpt provides broad earnings-season context, but reports no Edwards Lifesciences-specific results or developments.
Edwards Lifesciences discussed results from the CLASP II TR and PROGRESS trials, covering tricuspid and TAVR topics, in a transcript.
Why it matters — The discussion provides EW watchers with company commentary on clinical trial results related to its tricuspid and TAVR areas.
The 30 Wall Street analysts covering Edwards Lifesciences Corp. have a median 12-month price target of $103, with estimates ranging from $84 to $117. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 30 analysts covering Edwards Lifesciences Corp., 24 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edwards Lifesciences Corp. 91 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Edwards Lifesciences Corp. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (90 of 100).
No one can know that. What the data says: the median 12-month target from 30 analysts implies +3.8% from the last close, and Ticker Nerd's factor model ranks Edwards Lifesciences Corp. 91 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Edwards Lifesciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $117 over the next 12 months.
Edwards Lifesciences Corp. returned +18.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript". The item is a transcript of Edwards Lifesciences Corporation’s Q3 2026 earnings call; the excerpt provides no further details about the discussion.
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.
CEO Mr. Bernard J. Zovighian · 16,000 employees · United States · https://www.edwards.com
